Incyte Corporation (INCY : NASDAQ)
Common Stock
$116.87
USD
+0.27 (0.23%)
Last updated: 2026-10-28
Follow INCY
INCY
Incyte Corporation
WealthAwesomePerformance
1 Day
+0.23%
1 Week
+3.02%
1 Month
-6.37%
YTD
+15.23%
Key Statistics
Market Cap
$23.63B
52W High
$132.60
52W Low
$89.25
P/E Ratio
14.85
50 Day MA
$120.99
200 Day MA
$107.87
Beta
0.74
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/28/2026 | $115.50 | $118.49 | $114.74 | $116.87 | $116.87 | 1,771,774 |
| 10/27/2026 | $111.18 | $116.76 | $111.18 | $116.60 | $116.60 | 2,180,576 |
| 10/26/2026 | $115.48 | $115.92 | $112.75 | $113.31 | $113.31 | 2,152,669 |
| 10/23/2026 | $116.75 | $116.87 | $115.12 | $115.71 | $115.71 | 1,476,800 |
| 10/22/2026 | $113.93 | $117.17 | $112.76 | $116.93 | $116.93 | 2,134,154 |
| 10/21/2026 | $115.98 | $116.57 | $113.35 | $113.44 | $113.44 | 1,387,198 |
| 10/20/2026 | $113.78 | $117.00 | $113.26 | $116.61 | $116.61 | 1,245,975 |
| 10/19/2026 | $113.19 | $114.38 | $112.71 | $113.25 | $113.25 | 1,189,780 |
| 10/16/2026 | $113.98 | $114.57 | $112.02 | $113.07 | $113.07 | 1,580,200 |
| 10/15/2026 | $112.71 | $116.03 | $112.60 | $113.27 | $113.27 | 1,940,500 |
Analyst Price Targets
Based on 28 analysts covering INCY · as of Oct 26, 2026
Wall Street analysts forecast INCY stock price to rise 10.8% over the next 12 months.
Consensus
Buy3.75 / 5.00
Avg. Target
US$129.54
+10.8% Upside
Previously US$129.58 on Oct 23, 2026
Current Price
US$116.87
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on INCY's historical volatility
30-Day Vol
28.5%
Annualized
90-Day Vol
31.9%
Annualized
Trend (90d)
-13.2%
Annualized drift
90d Mean
US$111.49
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$115.05 | US$104.27 – US$126.94 |
| 60 trading days | US$113.26 | US$98.55 – US$130.16 |
| 90 trading days | US$111.49 | US$94.03 – US$132.20 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Financials
- Revenue (TTM)
- $5.82B
- EBITDA
- $1.94B
- Profit Margin
- 27.71%
- ROE (TTM)
- 30.67%
- EPS (Diluted)
- 7.85
- Book Value
- 31.57
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About INCY.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| AXG | Solowin Holdings | $5.68 | +14100.00% |
| ATYR | aTyr Pharma, Inc. | $5.14 | +4041.94% |
| OMEX | Odyssey Marine Exploration Inc | $13.55 | +2418.59% |
| HVII | Hennessy Capital Investment Corp. VII Ordinary Shares | $4.46 | +243.08% |
| ULBI | Ultralife Corporation | $15.61 | +145.44% |
| ATII | Archimedes Tech SPAC Partners II Co. Ordinary Shares | $9.81 | +110.06% |
| RITRF | Reitar Logtech Holdings Limited | $0.02 | +86.09% |
| KPTI | Karyopharm Therapeutics Inc | $0.83 | +73.35% |
INCY.US news timeline
4 articles covering INCY.US, most recent first
Latest